Evolus logo

EvolusNASDAQ: EOLS

Profile

Sector:

Healthcare

Country:

United States

IPO:

08 February 2018

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$1.06 B
-5%vs. 3y high
74%vs. sector
-vs. 3y high
-vs. sector
-36%vs. 3y high
100%vs. sector
-32%vs. 3y high
57%vs. sector

Price

pre-market | 33 min ago
$16.75-$0.11(-0.65%)

Dividend

No data over the past 3 years
$66.91 M$62.24 M
$66.91 M-$11.35 M

Analysts recommendations

Institutional Ownership

EOLS Latest News

Evolus to Participate in Stifel 2024 Healthcare Conference
businesswire.com01 November 2024 Sentiment: POSITIVE

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET. The presentation can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus.

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation
businesswire.com31 October 2024 Sentiment: POSITIVE

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme® (pronounced “esteem”), branded as Evolysse™ in the U.S. market. This certification marks a key regulatory milestone for Evolus, enabling it to commercially enter the der.

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com11 October 2024 Sentiment: POSITIVE

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,251 shares of Evolus and an aggregate of 31,049 restricted stock units (RSUs) of the company's common stock to 16 newly hired non-executive employees of the company. Additionally, the compensation committee approved the grant of individually nego.

Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
zacks.com31 July 2024 Sentiment: POSITIVE

Evolus, Inc. (EOLS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.22 per share a year ago.

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products
businesswire.com24 June 2024 Sentiment: POSITIVE

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF). “We are pleased to have submitted the final module of the PMA application,” said Dr. Rui.

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com07 June 2024 Sentiment: POSITIVE

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 30,778 shares of Evolus and an aggregate of 29,546 restricted stock units (RSUs) of the company's common stock to 9 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of.

4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Zacks Investment Research03 May 2024 Sentiment: POSITIVE

Some prominent companies currently experiencing strong growth in earnings include Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS), and Expro Group Holdings (XPRO).

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028
Seeking Alpha20 March 2024 Sentiment: POSITIVE

Evolus, a global performance beauty company, raised $60m in its IPO in 2018. Its first and only commercial product, Jeuveau, is an injectable botulinum toxin Type A product that has been approved in the US and most European territories. Evolus has settled a lawsuit with AbbVie and is focused on taking on Botox in the commercial markets.

4 Stocks to Buy for Attractive Earnings Acceleration
Zacks Investment Research15 March 2024 Sentiment: POSITIVE

Invest in stocks such as Protagonist Therapeutics (PTGX), Evolus (EOLS), Western Digital (WDC), and Phunware (PHUN) as of now for superb earnings acceleration.

Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect?
Zacks Investment Research13 March 2024 Sentiment: POSITIVE

The consensus price target hints at a 63.2% upside potential for Evolus, Inc. (EOLS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What type of business is Evolus?

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

What sector is Evolus in?

Evolus is in the Healthcare sector

What industry is Evolus in?

Evolus is in the Drug Manufacturers - Specialty & Generic industry

What country is Evolus from?

Evolus is headquartered in United States

When did Evolus go public?

Evolus initial public offering (IPO) was on 08 February 2018

What is Evolus website?

https://www.evolus.com

Is Evolus in the S&P 500?

No, Evolus is not included in the S&P 500 index

Is Evolus in the NASDAQ 100?

No, Evolus is not included in the NASDAQ 100 index

Is Evolus in the Dow Jones?

No, Evolus is not included in the Dow Jones index

When was Evolus the previous earnings report?

No data

When does Evolus earnings report?

The next expected earnings date for Evolus is 06 November 2024